Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Securities And Exchange Commission v. Ferrone et al
Case Number:
1:11-cv-05223
Court:
Nature of Suit:
Judge:
Firms
Government Agencies
-
July 05, 2016
SEC Seeks To Banish Ex-Pharma CEO After Fraud Verdict
The U.S. Securities and Exchange Commission on Monday urged an Illinois federal judge to bar the former leader of a drug company whose sole product was derived from goat's blood from serving on public companies' boards, saying his bid to soften his penalties is counter to his jury verdict for securities fraud.
-
June 24, 2016
Ex-Pharma CEO Says SEC Call For Banishment Too Harsh
The onetime leader of a drug company whose sole product was derived from goat’s blood on Thursday asked an Illinois federal judge to deny the U.S. Securities and Exchange Commission’s request that he be barred from serving on the board of any other public company following a verdict that went in the SEC’s favor.
-
April 29, 2016
Pharma CEO Hid FDA Hold From Investors, Jury Finds
The CEO of Immunosyn Corp., a drugmaker whose sole product was derived from goat's blood, was responsible for upselling investors on the drug's promise by not warning them that the U.S. Food and Drug Administration blocked the drug's approval process, an Illinois federal jury found Friday.
-
April 28, 2016
Pharma CEO Says He's An Honest Guy As SEC Trial Wraps
Attorneys for the CEO of a pharmaceutical company admonished the U.S. Securities and Exchange Commission's "harsh and hurtful words" Thursday, saying the agency couldn't prove their client was lying to investors while promoting an experimental medication made from goat's blood.
-
April 19, 2016
Immunosyn CEO Hid FDA Hold From Investors, Jury Told
The CEO of publicly traded biopharmaceutical company Immunosyn Corp. hid regulators' concerns about the company's only drug from investors in an effort to keep its stock price high, the U.S. Securities and Exchange Commission told a jury in Illinois federal court Tuesday.
-
January 14, 2016
Pharma Execs Banned From Leading Drug Cos. In Insider Case
Two executives at pharmaceutical company Immunosyn Corp. were permanently banned from leading any drug company Thursday after an Illinois federal judge found they had willfully misrepresented their drug's success to investors to raise money and then sold their shares when the drug's trials were put on hold.
-
August 02, 2011
Immunosyn Execs Hit With $20M Insider Trading Suit
Executives at San Diego biotechnology firm Immunosyn Corp. hyped an experimental HIV drug, raising $20 million from investors, then sold their shares without disclosing that the drug's approval process was on hold, regulators claimed Monday in an Illinois insider trading suit.